Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT07028125 | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma(CANIQOL) | recruiting | Phase 4 | 83 | Centre Francois BaclesseOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06903312 | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.(ITALIC-RCC) | recruiting | Phase 4 | 409 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05805436 | Preop Laxatives in Robotic Urologic Surgery | recruiting | Phase 4 | 240 | Chad R. TracyOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | terminated | Phase 4 | 12 | Indiana UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery | terminated | Phase 4 | 21 | University of Missouri-ColumbiaOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02982954 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer(CHECKMATE 920) | completed | Phase 4 | 211 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02596035 | An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma(CheckMate 374) | completed | Phase 4 | 197 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00414765 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | completed | Phase 4 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04162834 | Effect of Papaverine on Renal Artery Blood Flow Volume | completed | Phase 4 | 96 | Asan Medical CenterOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)(ORCHIDEE) | terminated | Phase 4 | 31 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01266837 | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)(MARC-2) | completed | Phase 4 | 64 | iOMEDICO AGINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00666978 | Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking | completed | Phase 4 | 540 | Lisa Sanderson Cox, PhDOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01521715 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma(FLIPPER) | completed | Phase 4 | 44 | iOMEDICO AGINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02988219 | Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method | completed | Phase 4 | 50 | Medical University of WarsawOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00172003 | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00365508 | Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking | completed | Phase 4 | 642 | Fox Chase Cancer CenterOTHER | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma(PREINSUT) | terminated | Phase 4 | 33 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | terminated | Phase 4 | 2 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT01486550 | Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy(VONE) | terminated | Phase 4 | 14 | Regional Hospital HolstebroOTHER | 1 | Oct 9, 2014 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00006864 | Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 4 | — | Case Comprehensive Cancer CenterOTHER | 1 | Jan 9, 2014 | clinicaltrials |
| NCT00706706 | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma(MRCC RCC) | completed | Phase 4 | 105 | PfizerINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00777504 | Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | unknown | Phase 4 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 16, 2011 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials